• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

An investigation of the molecular mechanisms of action of lenalidomide in adult T-cell leukemia (ATL)

Research Project

Project/Area Number 17K14996
Research Category

Grant-in-Aid for Young Scientists (B)

Allocation TypeMulti-year Fund
Research Field Tumor biology
Research InstitutionTokyo Medical University

Principal Investigator

Yamamoto Junichi  東京医科大学, 医学部, 助教 (40748472)

Project Period (FY) 2017-04-01 – 2019-03-31
Project Status Completed (Fiscal Year 2018)
Budget Amount *help
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2018: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2017: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Keywordsがん / 成人T細胞白血病 / IMiDs / 癌
Outline of Final Research Achievements

Lenalidomide, a thalidomide derivative, is approved for adult T-cell leukemia / lymphoma (ATL) in Japan. However, the underlying mechanisms are not clear. In this study, we attempted to identify novel substrates of CRBN, a direct target of lenalidomide, in ATL cell lines. As a result, we identified 12 novel substrates of CRBN that were specifically degraded by treatment of lenalidomide or lenalidomide derivatives in ATL cell line.

Academic Significance and Societal Importance of the Research Achievements

日本には100万人を超えるHTLV-1キャリアが存在し、毎年1000人近くの患者がATLによって亡くなっており、ATLに対する有効な治療法の確立は我が国にとって急務といえる。
本研究でATLに有効な治療薬であるレナリドミドの標的候補が同定されたことによって、その作用機序の解明が進み、より効果的な治療薬の開発に繋がると考えられる。

Report

(3 results)
  • 2018 Annual Research Report   Final Research Report ( PDF )
  • 2017 Research-status Report

URL: 

Published: 2017-04-28   Modified: 2020-03-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi